# ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

> **NCT04578613** · PHASE3 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 218 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** ICP-022
- **DRUG:** Chlorambucil
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04578613
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-08
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578613, "ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04578613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*